GLP-1 Peptide Atlas, by Delfa

CompletedPhase 3

Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination

An Open-Label Study to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety of AC2993 Given Two Times a Day to Subjects With Type 2 Diabetes Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination

Lead sponsor

AstraZeneca

Asset

Exenatide

GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

155

actual

Study population

Type 2 diabetes

Key I/E criteria

•BMI 25-45•HbA1c 7.5-12%

Primary endpoints

•HbA1c, change•Fasting glucose, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT00044668

Org study ID2993-117

Timeline

Milestones

Study first posted2002-09-05estimated

Last update posted2015-02-20estimated

Study start2002-08 (month precision)

Primary completion2005-09actual (month precision)

Study completion2005-09actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Subjects with type 2 diabetes

•Treated for at least 3 months prior to screening either with metformin, sulfonylurea, or metformin and sulfonylurea combination

•BMI 25-45 kg/m^2

•HbA1c between 7.5 % and 12.0 %, inclusive

Exclusion criteria

•Treated with other oral anti-diabetic agents other than metformin and sulfonylureas within 3 months of screening

•Patients previously treated with AC2993

•Patients presently treated with insulin

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints

Primary/protocol endpoint

Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 24, Week 52, and to each intermediate visit

Time frame:Baseline, and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Primary/protocol endpoint

Change in concentrations of fasting plasma glucose and lipids from Baseline Visit 2 (Day 1) to Week 24, to Week 52, and to each intermediate visit

Time frame:Baseline, and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, and 52

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Diabetes, obesity & metabolism2012 Jun (month)PMID22236356doi:10.1111/j.1463-1326.2012.01561.xvia clinicaltrials gov reference derived + pubmed nct search
Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Clinical therapeutics2012 Jun (month)PMID22608106doi:10.1016/j.clinthera.2012.04.022via clinicaltrials gov reference derived + pubmed nct search

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.